Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy
Attractive market fundamentals | Leadership and scale | Multiple growth drivers | Margin improvement | Attractive financial outlook | Compelling sustainability story
A
Focused on sales execution
Europe
Building on our
leadership position
50%
of total Sandoz net sales
•
#1 in Generics and Biosimilars
•
Capitalize on our footprint,
portfolio and pipeline
North America
Stabilizing and
returning to growth
23%
•
of total Sandoz net sales
Leading in segments
where we compete
Four high-value upcoming
Biosimilars launches
International
Capturing high-growth /
high-return opportunities
27%
of total Sandoz net sales
• Targeting attractive markets
Leveraging our portfolio globally,
supplemented by M&A and BD&L
Note: Net sales to third parties based on unaudited carve-out financials extract
13
Management Presentation
SANDOZView entire presentation